Detailed explanation of the latest price and medical insurance reimbursement of Dabrafenib

Dabrafenib is an oral BRAF inhibitor that mainly targets BRAF V600 mutation-positive tumors. By inhibiting abnormally activated BRAF kinase and blocking the MAPK signaling pathway, it inhibits tumor cell proliferation and induces apoptosis. Clinically, dabrafenib is often used in patients with BRAF V600 mutated melanoma, non-small cell lung cancer and some thyroid cancers to provide effective targeted treatment options for mutant tumors.

Dabrafenib has been officially launched in China and has been included in the national medical insurance system. This means that patients who are eligible for medical insurance reimbursement can enjoy partial cost reimbursement, thereby reducing their financial burden. Specific medical insurance reimbursement policies and payment ratios vary by region. Patients need to consult local medical insurance policies at the hospital or pharmacy to clarify the self-pay amount and reimbursement process.

In the domestic market, the latest selling price of dabrafenib75mg 120 tablets is between more than 9,000 to more than 10,000 yuan, and the actual payment amount after specific medical insurance reimbursement needs to be determined according to regional policies. In foreign markets, the Turkish original research version 75mg 120 capsules is priced at about 11,000 yuan, which is relatively high. The generic version of dabrafenib approved by the Ministry of Health of Laos is more affordable, only about 2,000 yuan, and its ingredients are basically the same as the original drug, providing a viable option for patients with limited financial ability.

Clinically, dabrafenib usually needs to be used in combination with trametinib (Trametinib) to delay the development of drug resistance and improve efficacy. Patients need to regularly monitor liver function, blood sugar, blood pressure and electrocardiogram during medication, and pay attention to common adverse reactions such as rash, fever or fatigue. For patients with different economic conditions, appropriate drugs can be selected based on domestic original drugs, medical insurance reimbursement status, and overseas or generic drug prices. At the same time, treatment courses can be reasonably arranged under the guidance of doctors to ensure safe, continuous treatment and optimal efficacy.

Reference materials:https://www.drugs.com/